PDLIM2 as a biomarker for cancer and as an anti-cancer treatment target
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsZhaoxia Qu, Gutian Xiao
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and compositions for treating cancer (e.g., lung cancer) in a subject by increasing the expression of PDZ-LIM domain containing protein 2 (PDLIM2) in the subject, or a functional fragment thereof. The present disclosure further provides methods of using PDLIM2 as a marker for determining and monitoring a subject's responsiveness to an anti-cancer treatment, providing a prognosis about a cancer in a subject, and selecting an effective anti-cancer treatment for a subject. The present disclosure also provides in vitro methods of screening anti-cancer agents by assessing whether the expression of PDLIM2 is restored by an anti-cancer agent in a cancer cell.
Claims12
A method for treating a subject having a cancer, comprising administering to the subject an agent for increasing the expression of PDZ-LIM domain containing protein 2 (PDLIM2), or a functional fragment thereof, and a second anti-cancer treatment selected from the group consisting of a chemotherapy, a radiotherapy, a targeted drug therapy, an immunotherapy, and a combination thereof, in the subject;
- wherein the agent is an epigenetic modulating agent selected from the group consisting of DNA methyltransferase inhibitor, histone deacetylase inhibitor, and combination thereof.
Dependencies are inferred from the claim text.